Royalty Pharma plc - Ordinary Shares - Class A

-0.05 (-0.15%)
6:10:49 PM EDT: $33.92 +0.13 (+0.39%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)15.14B
Current PE24.78
Forward PE 8.22
2yr Forward PE 8.64
See more stats
Estimates Current Quarter
Revenue$562.9 Million
Adjusted EPS$0.82
See more estimates
10-Day MA$33.41
50-Day MA$34.62
200-Day MA$38.26
See more pivots

Royalty Pharma plc - Ordinary Shares - Class A Stock, NASDAQ:RPRX

110 East 59th Street, 33rd floor, New York, New York 10022
United States of America
Phone: +1.212.883.0200
Number of Employees: 75


Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J�s Imbruvica, Astellas and Pfizer�s Xtandi, Biogen�s Tysabri, Gilead�s HIV franchise, Merck�s Januvia, Novartis� Promacta, Vertex�s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.